Byrna Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Byrna Technologies Inc trades at $3.6 (market cap $80.33M), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 22.2× Byrna Technologies Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BYRN | RXRX | |
|---|---|---|
Market Cap | $80.33M | $1.78B |
Sector | Technology | Health |
52-Week High | $27.63 | $6.79 |
52-Week Low | $3.54 | $2.84 |
Enterprise Value | $71.94M | $1.19B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Trailing returns across standard periods
Latest headlines on both assets
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →